The ICD in heart failure - time for a rethink? by McMurray, John J.V.
Edi tor i a l s
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 375;13 nejm.org September 29, 2016 1283
The ICD in Heart Failure — Time for a Rethink?
John J.V. McMurray, M.D.
In a number of primary-prevention trials, implant-
able cardioverter–defibrillators (ICDs) have been 
shown to reduce the risk of premature death among 
patients with left ventricular systolic dysfunction 
after myocardial infarction and among patients 
with heart failure and reduced ejection fraction.1 
The evidence of a benefit is less robust for patients 
with heart failure who do not have coronary artery 
disease; the single largest trial, involving 458 such 
patients, did not show a significant reduction in 
mortality in association with ICD therapy.2 As a 
result, the current guideline recommendations are 
based on a meta-analysis of small trials involving 
patients with nonischemic cardiomyopathy, as well 
as subgroups with nonischemic cardiomyopathy 
from larger trials.3 Against this background, in the 
Danish Study to Assess the Efficacy of ICDs in 
Patients with Non-ischemic Systolic Heart Failure 
on Mortality (DANISH), the results of which are 
now reported in the Journal, Køber and colleagues 
randomly assigned 1116 patients with nonisch-
emic heart failure to receive conventional therapy 
or an ICD added to conventional therapy and fol-
lowed them for a median of 5.6 years.4 Although 
ICD therapy was associated with a risk of sudden 
cardiac death that was half that associated with 
conventional therapy, the effect on overall mortal-
ity, the primary end point of the trial, was not 
significant.
How should we interpret these findings? That 
there was no significant benefit with regard to 
overall mortality in the DANISH trial was a result 
of the low risk of sudden cardiac death among the 
patients included in the trial. This low risk re-
flects two features of the trial. First, patients with 
nonischemic cardiomyopathy have lower rates of 
sudden cardiac death and of death from any cause 
than do patients with an ischemic cause of heart 
failure. Second, and probably more importantly, 
the background treatment in the trial was very 
comprehensive. The use of angiotensin-convert-
ing–enzyme inhibitors or angiotensin-receptor 
blockers and beta-blockers was almost universal, 
and close to 60% of patients were treated with a 
mineralocorticoid-receptor antagonist. In addition, 
and unlike in previous ICD trials, 58% of patients 
received cardiac-resynchronization therapy. Col-
lectively, these treatments reduce the risk of pre-
mature cardiovascular death, including the risk of 
sudden cardiac death, very substantially.1 In the 
control group in the trial, approximately 73% of all 
deaths were attributed to a cardiovascular cause, 
one of the lowest proportions ever described in 
a trial involving patients with heart failure.5 The 
declining rate of death from cardiovascular causes 
makes it harder to demonstrate a benefit of ad-
ditional therapy for heart failure with regard to 
overall mortality.5 This is especially so for ICDs, 
which modify only one of the two major modes 
of death, unlike pharmacologic therapies, which 
reduce the risk of death from worsening heart 
failure as well as the risk of sudden cardiac death. 
Consequently, with an ICD, there is not only the 
risk of death from noncardiovascular causes but 
also the risk from progressive pump failure and 
other cardiovascular causes. These competing risks 
change with time as heart failure advances (and 
the risk of nonsudden death rises), and noncardio-
vascular causes of death become more frequent 
with increasing age and increasing numbers of 
coexisting conditions. Thus, the combination of 
a low overall mortality rate and a relatively small 
proportion of deaths due to cardiovascular causes, 
with only approximately a third of deaths in the 
control group occurring suddenly, made it diffi-
cult to show a significant benefit of ICD therapy 
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with regard to the risk of death from any cause 
with the number of patients enrolled. Moreover, 
any such benefit was likely to decline with time, 
as seems to have been the case.
What are the implications of these findings 
for clinical practice? The results of the DANISH 
trial probably represent the most optimistic esti-
mate of the benefit of ICD therapy in patients 
with nonischemic heart failure who receive evi-
dence-based treatment. Patients enrolled in trials 
are usually younger and have fewer coexisting 
conditions than do those in the community and, 
as a consequence, have a relatively higher risk of 
death from cardiovascular causes than from non-
cardiovascular causes.6,7 In keeping with this ob-
servation, there was a suggestion of a differential 
response according to age in the present trial, 
with a possible benefit of ICD therapy with regard 
to death from any cause among younger patients 
(<68 years of age). The background rate of death 
from cardiovascular causes and sudden cardiac 
death could also be reduced even more in prac-
tice by further optimizing pharmacologic therapy, 
with greater use of mineralocorticoid-receptor 
antagonists and new treatments shown to reduce 
risk in heart failure, as well as the use of coronary 
revascularization in patients with ischemic car-
diomyopathy.8,9 Consequently, the absolute ben-
efit of ICDs in a typical and well-treated popula-
tion with heart failure might be small. ICDs are 
expensive and not without adverse effects. It is, 
therefore, desirable to avoid their use in patients 
who are unlikely to obtain a worthwhile benefit. 
These considerations highlight the need to target 
ICDs to the patients most likely to benefit — that 
is, those who remain at high absolute risk for sud-
den cardiac death despite receiving the best avail-
able pharmacologic and device therapy. The results 
of the DANISH trial, coupled with the generally 
infrequent use of ICDs globally, should open a 
debate about whether it is ethical to conduct new 
ICD trials involving the highest-risk patients. The 
challenge is how to identify such patients.10
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Antibiotic Prophylaxis for Cesarean Delivery —  
When Broader Is Better
Robert A. Weinstein, M.D., and Kenneth M. Boyer, M.D.
Approximately 4 million babies are born each year 
in the United States. Of these infants, about a third 
are delivered by cesarean section. One of the many 
concerns about cesarean deliveries is the high risk 
of maternal infectious complications, which are 
5 to 10 times more frequent than with vaginal 
deliveries.1 During cesarean delivery, the endo-
metrial cavity and operative field may be seeded 
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